O'Dwyer M - Search Results

1

Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma.

Vincenz L, Jäger R, O'Dwyer M, Samali A. Vincenz L, et al. Mol Cancer Ther. 2013 Jun;12(6):831-43. doi: 10.1158/1535-7163.MCT-12-0782. Epub 2013 May 31. Mol Cancer Ther. 2013. PMID: 23729400 Review.

2

Drugging the unfolded protein response in acute leukemias.

Kharabi Masouleh B, Chevet E, Panse J, Jost E, O'Dwyer M, Bruemmendorf TH, Samali A. Kharabi Masouleh B, et al. J Hematol Oncol. 2015 Jul 16;8:87. doi: 10.1186/s13045-015-0184-7. J Hematol Oncol. 2015. PMID: 26179601 Free PMC article. Review.

3

Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.

Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C. Natoni A, et al. Mol Cancer Ther. 2011 Sep;10(9):1624-34. doi: 10.1158/1535-7163.MCT-10-1119. Epub 2011 Jul 18. Mol Cancer Ther. 2011. PMID: 21768328

4

Targeting AML through DR4 with a novel variant of rhTRAIL.

Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ, Samali A. Szegezdi E, et al. J Cell Mol Med. 2011 Oct;15(10):2216-31. doi: 10.1111/j.1582-4934.2010.01211.x. J Cell Mol Med. 2011. PMID: 21070598 Free PMC article.

5

TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.

Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A. Szegezdi E, et al. Br J Cancer. 2006 Feb 13;94(3):398-406. doi: 10.1038/sj.bjc.6602954. Br J Cancer. 2006. PMID: 16434995 Free PMC article.

6

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.

O' Reilly E, Dhami SPS, Baev DV, Ortutay C, Halpin-McCormick A, Morrell R, Santocanale C, Samali A, Quinn J, O'Dwyer ME, Szegezdi E. O' Reilly E, et al. Sci Rep. 2018 Oct 25;8(1):15752. doi: 10.1038/s41598-018-33982-y. Sci Rep. 2018. PMID: 30361682 Free PMC article.

7

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.

Dijk Mv, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A, Szegezdi E. Dijk Mv, et al. Cancers (Basel). 2011 Mar 15;3(1):1329-50. doi: 10.3390/cancers3011329. Cancers (Basel). 2011. PMID: 24212664 Free PMC article.

8

Targeting the Pim kinases in multiple myeloma.

Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M. Keane NA, et al. Blood Cancer J. 2015 Jul 17;5(7):e325. doi: 10.1038/bcj.2015.46. Blood Cancer J. 2015. PMID: 26186558 Free PMC article. Review.

9

AKT as a therapeutic target in multiple myeloma.

Keane NA, Glavey SV, Krawczyk J, O'Dwyer M. Keane NA, et al. Expert Opin Ther Targets. 2014 Aug;18(8):897-915. doi: 10.1517/14728222.2014.924507. Epub 2014 Jun 6. Expert Opin Ther Targets. 2014. PMID: 24905897 Review.

10

RNA interference for multiple myeloma therapy: targeting signal transduction pathways.

Guo J, McKenna SL, O'Dwyer ME, Cahill MR, O'Driscoll CM. Guo J, et al. Expert Opin Ther Targets. 2016;20(1):107-21. doi: 10.1517/14728222.2015.1071355. Epub 2015 Jul 20. Expert Opin Ther Targets. 2016. PMID: 26190583 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page